Stay connected
Pfizer CEO Albert Bourla warned Tuesday that others who do not take the Covid-19 vaccine will have a “weak link” that will allow the coronavirus to spread.
Bourla, whose company is lately conducting complex tests for inoculation imaginable, said it understands public considerations about vaccines, that they are developing in record time, and that Pfizer will only seek approval from the Food and Drug Administration after knowledge proves that your vaccine is safe and effective.
But he also said that other people who make the decision not to take the vaccine once they have had it “will not only affect their lives. “
They “will want the lives of others because if they are not vaccinated, they will become the weak link that will allow this virus to replicate,” he told NBC “TODAY. “
Vaccination hesitation was already a challenge in the United States, but concern about the Trump administration’s pandemic and communication about vaccine progression have exacerbated opposition to a vaccine and may jeopardize the effect of a Covid-19 vaccine, infectious disease experts and scientists say.
Medical experts are also concerned that approval of a vaccine may be politically motivated, as the Trump administration pressures states to have vaccine distribution sites in a position on November 1, two days before the presidential election.
According to a recent USA TODAY / Suffolk vote, two-thirds of the electorate say they will get the coronavirus vaccine as soon as it is available. His ballot from the Associated Press-NORC Public Affairs Research Center found that only 49% of Americans say they plan to take an anti-Covid-19 vaccine once it becomes available.
Early Tuesday, an organization of drug manufacturers, Pfizer, pledged to “maintain the integrity of the clinical process”, as it is based on regulatory filings and approval of the first Covid-19 vaccines.
The move comes after FDA commissioner Dr. Stephen Hahn told the Financial Times last week that the company was ready to ignore the full federal approval procedure so it could get a vaccine as soon as possible.
Insisting that President Donald Trump do not pressure the company to accelerate the implementation of the vaccine, Hahn said an emergency authorization would possibly be appropriate before phase three clinical trials are completed if the benefits outweigh the risks.
It also came after news that the Centers for Disease Control and Prevention had asked governors and fitness departments to prepare to distribute a vaccine in early November.
“We need other people to know that, also in the current scenario, we are not ready to compromise protection and efficiency,” said co-signer Ugur Sahin, CEO of German partner Pfizer BioNTech.
Bourla called commitment a “historical promise” and added that the global is “turning to science. “
Last week, he said the company could have the effects of its complex coronavirus vaccine test starting in October after recruiting 23,000 volunteers.
“We felt it was imperative to faint and reiterate our commitment,” he said Tuesday. “We will expand our product, expand our vaccine to the highest moral standards. “
Do you have any confidential information? We want to hear you.
Sign up for loose newsletters and get more CNBC delivered to your inbox
Get it in your inbox and more information about our services.
© 2020 CNBC LLC. All rights are reserved. An NBCUniversal department
Knowledge is a real-time snapshot: data is delayed for at least 15 minutes, monetary and global industry news, inventory quotes, and market knowledge and analysis.
Data also by